December 2021 Content Release Copied
Clinical Profile Documentation
With the latest Health Language Inc. (HLI) load to the Generation 2 application SNOMED-CT terminology has been updated per SNOMED standards:
- Quality improvement tasks were deployed to improve internal structural consistency and ensure compliance with editorial policy related to the stated modeling of content.
- Correction or addition of defining relationships was carried out to accurately reflect current clinical knowledge and ensure the semantic reliability of descriptions associated with a concept.
Additions
The following items are available for documentation in Problems and appear on the Charge Capture Report (CCR).
NOTE: The ICD10 code choice(s)* below are not an exclusive list of codes for each problem row.
| Problem | ICD-10 Code Choice(s)* |
| Chest pain | R07.81 Pleurodynia R07.82 Intercostal pain R07.89 Other chest pain R07.9 Chest pain, unspecified |
| Leukopenia (disorder) | D72.818 Other decreased white blood cell count |
| Postprocedural seroma | L76.34 Postprocedural seroma of skin and subcutaneous tissue following other procedure |
| Thromboembolism of vein | I82.91 Chronic embolism and thrombosis of unspecified vein |
| Venous thrombosis | I82.91 Chronic embolism and thrombosis of unspecified vein |
Updates
The Problems > Add Details area is updated with applicable documentation points for the following diagnoses:
- Thromboembolism of vein
Medications
Additions
- AMG 160 invest IV
- Bemarituzumab (AMG 552) invest IV
- Besremi (Ropeginterferon alfa-2b-njft Subcutaneous)
- Camrelizumab (SHR-1210) invest IV
- ERAS-007 invest Oral
- Evusheld (Tixagevimab-Cilgavimab IM Dose Pack 150 mg/1.5 mL-150 mg/1.5 mL (EUA))
- Fyarro (Sirolimus-Protein Bound IV)
- KIN-2787 invest Oral
- Mouthwash (Tacrolimus-Dexamethasone) Oral Liquid
- Ropeginterferon alfa-2b-njft Subcutaneous
- Sirolimus-Protein Bound IV
- T3011 1x10e6 pfu invest IV
- T3011 1x10e7 pfu invest IV
- T3011 1x10e8 pfu invest IV
- TH1902 invest IV
- TransCon TLR7/8 Agonist invest Intratumoral
Updates
- HepaGam B (Hepatitis B Immune Globulin-Maltose IV)
- Added new unit: mL
- Mosunetuzumab invest Subcutaneous (BTCT4465A invest Subcutaneous)
- Synonym is now available
Regimens
Additions
- Daratumumab IV + Carfilzomib D1,8,15 + Lenalidomide + Dexamethasone Q28D
- Etoposide D1-4 + Ifosfamide Bolus D1-4 + Cisplatin D1-4 (VIP) Q21D (Thymoma)
- Pembrolizumab + Paclitaxel + Carboplatin + Bevacizumab Q21D (Cervical)
- Pembrolizumab + Paclitaxel + Cisplatin + Bevacizumab Q21D (Cervical)
- Pembrolizumab + Paclitaxel + Cisplatin Q21D (Cervical)
- Pemetrexed + Cisplatin + Bevacizumab Q21D (Mesothelioma)
- Megestrol D1-21 alternating with Tamoxifen D22-42 Q42D
- Neratinib Dose Titration + Capecitabine D1-14 Q21D
- Tixagevimab-Cilgavimab (Evusheld) (COVID-19 Pre-Exposure Prophylaxis)
Updates
Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.
- Cervical Cancer
- Colon Cancer
- Endometrial Cancer
- Fallopian Tube Cancer
- Head and Neck Cancer (Parent)
- Lung Cancer, Non-small Cell (NSCLC)
- Malignant Mesothelioma
- Malignant Pleural Mesothelioma
- Melanoma, Skin
- Multiple Myeloma (MM)
- Ovarian and Primary Peritoneal Cancer
- Rectal Cancer
- Renal Cell Cancer (RCC)
- Uterine Cancer (Parent)
Renames
| Previous Name | New Name |
| Fluorouracil (Bolus + CIV) D1-2 + Leucovorin D1 + Oxaliplatin D1 (FOLFOX 6, Modified) + Panitumumab Q14D | Fluorouracil (Bolus + CIV) D1-2 + Leucovorin + Oxaliplatin (FOLFOX 6, Modified) + Panitumumab Q14D |
| Pembrolizumab Q21D (Flat Dose, Adjuvant Melanoma) | Pembrolizumab Q21D (Flat Dose) (Adjuvant Melanoma, RCC) |
| Pembrolizumab Q42D (Flat Dose, Adjuvant Melanoma) | Pembrolizumab Q42D (Flat Dose) (Adjuvant Melanoma, RCC) |
| Pembrolizumab Q42D (Dose Banding, Adjuvant Melanoma) | Pembrolizumab Q42D (Dose Banding) (Adjuvant Melanoma, RCC) |
Removals
- Alemtuzumab (Campath) D1,3,5 Q7D (Maintenance)
- Alemtuzumab (Campath) Q7D (Initial)
Research
Additions
To support Data Migration, applicable clinical trial regimens for US Oncology Research have been migrated and modified for customers migrating from iKnowMed Generation 1 to iKnowMed Generation 2.
Updates
| Updated Reference Information | Updated Drug Service Order Information | Updated Regimen Instructions | Other Changes | |
| USOR 16104 | X | X | ||
| USOR 17188 | X | X | X | |
| USOR 17194 | X | |||
| USOR 18095 | X | |||
| USOR 18229 | X | X | ||
| USOR 19018 | X | X | ||
| USOR 19092 | X | |||
| USOR 19151 | X | X | X | Now available for ordering:
USOR 19151 MRTX849 + Cetuximab D1,15 Q28D |
| USOR 19182 | X | X | ||
| USOR 19205 | X | X | X | |
| USOR 19236 | X | |||
| USOR 20235 | X | X | ||
| USOR 20343 | X | X | X | |
| USOR 20409 | X | X | X | Now available for ordering:
USOR 20409 Arm 2 Tucatinib (PO; BID) + Cinrebafusp Alfa D1,15 Q28D |
| USOR 20414 | X | X | X | |
| USOR 21219 | X | |||
| USOR 21400 | X |
Billing: HCPCS & CPT Codes
- Complete list of January 2022 updates: CMS HCPCS Quarterly Updates
- Complete details on CMS HCPCS Coding Decisions
HCPCS Updates
NOTIFICATION: Effective Jan 1, 2022*:
- The HCPCS code and billing dose for Pegfilgrastim (excluding bioisimilar) will change from J2505 per 6 mg to J2506 per 0.5 mg
| Medication | HCPCS Code |
| Abecma (Idecabtagene Vicleucel IV | Q2055 per 300, 450, 460 x 10e6 CARpos viable T cells |
| Aduhelm (Aducanumab-avwa, IV) | J0712 per 2 mg |
| Available on 1/5/22 per FDB:
Camcevi (Leuprolide) |
J1952 per 1 mg |
| Evusheld (Tixagevimab IM (1 of 2) (EUA)) | J3590 per 150 mg |
| Evusheld (Cilgavimab IM (2 of 2) (EUA)) | J3590 per 150 mg |
| Factor IX Complex IV | J7194 per 1 unit |
| Factor IX Human (Recom Thr148) IV | J7195 per 1 unit |
| Factor IX Recomb, Fc Fusion Protein IV | J7201 per 1 unit |
| Fyarro (Sirolimus-Protein Bound IV) | J9999 per 100 mg |
| Jemperli (Dostarlimab-gxly IV) | J9272 per 10 mg |
| Ketamine Subcutaneous | J3490 per 10 mg |
| Lidocaine Intra-Articular | J2021 per
|
| Methylene Blue IV | Q9968 per 1 mg |
| Neulasta (Pegfilgrastim Subcutaneous)* | J2506 per 0.5 mg |
| Neulasta (Pegfilgrastim Subcutaneous (via wearable injector))* | J2506 per 0.5 mg |
| Ropeginterferon alfa-2b-njft (Besremi) Subcutaneous | J3590 per 500 mcg |
| Rybrevant (Amivantamab-vmjw IV) | J9061 per 2 mg |
| Rylaze (Asparaginase Erwinia-rywn IM) | J9021 per 0.1 mg |
| Ryplazim (Plasminogen, Human-tvmh IV) | J3490 per 68.8 mg |
| Vosoritide Subcutaneous | J3590 per –
|
CPT Updates
For the complete list of 2022 CPT updates please see the 2022 CPT Workbook document.
Summary of Total Changes – 405
- New Codes – 249
- Revised Codes – 93
- Deleted Codes – 63
Procedure Updates
Procedure mappings have been performed for the following synonyms to ensure CPT codes will display for charting and generate for charge capture report (CCR):
| Procedure Description | CPT Code |
| Anoscopy (procedure) | 46600 |
| Endometrial biopsy | 58100, 58110, 58558 |
| Punch biopsy of skin lesion (procedure) | 11104 |
| Punch biopsy of skin lesion (procedure) | 11105 |
Lab Analytes & Panels Additions
- A diagnosis, tissue pathology
- A gross description, tissue pathology
- A procedure, tissue pathology
- B diagnosis, tissue pathology
- B gross description, tissue pathology
- B procedure, tissue pathology
- B2 glycoprotein I ab, IgA, U/mL
- C. diff Toxin/GDH comment
- C. diff Toxin/GDH micro number
- C. diff Toxin/GDH report status
- C. diff Toxin/GDH source
- C. diff Toxin/GDH specimen quality
- C. diff Toxin/GDH w/Reflex to PCR panel
- C. difficile glutamate dehydrogenase antigen
- C. difficile toxins A + B
- Calc triglyceride/HDL
- Chlamydia trachomatis, NAA
- CMV Ab, IgG, AI
- CMV ab, IgG, U/mL
- CMV Ab, IgM result
- CMV Ab, IgM, AI
- CMV ab, IgM, AU/mL
- CSF histiocyte, %
- Cytomegalovirus IgM, IgG panel
- Fentanyl confirmation, blood
- Gabapentin confirmation, blood
- Hepatitis B core antibody, total
- Hepatitis B immunity interpretation
- Hepatitis B profile X (immunity status) panel
- Hepatitis B profile X reflex to HBC IgM
- Hepatitis B surface ab, qual
- Hepatitis B surface antigen screen
- HIV-1 DNA, qual RT PCR
- HIV-1 DNA, qual RT PCR panel
- HSV 1 IgG result
- HSV 1 NAA
- HSV 1 specific Ab, IgG
- HSV 2 NAA
- Immunotyping urine comment
- Iron panel (FE, TIBC)
- Iron profile (FE, TIBC, Ferritin)
- Lymph2Cx test
- Lymph3Cx test
- Neisseria gonorrhoeae, NAA
- NuSwab STD – Ct Ng TV HSV panel, NAA
- Pleximark (TM) panel
- S. rectivirgula Ab, qual
- SM ab, EU
- SM/RNP ab, EU
- Soluble IL-2R panel
- Soluble IL2R
- Soluble IL-2R assay description
- Tissue pathology panel
- Tissue pathology, clinical Information
- Tissue pathology, pathologist
- Tissue pathology, report notes
- Trichomonas vaginalis, NAA
- Yo Ab screen w/ Reflex to titer and western blot
- Yo Ab, western blot, serum